Zepbound vs Wegovy: Two Weight-Management Injections

Last reviewed: May 12, 2026 Last updated: May 12, 2026

Written by: Jay Hastings , CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance. His work has included scaling healthcare startups, leading CLIA lab integrations, and helping expand consumer access to precision health tools.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

The PlexusDx Education Hub covers GLP-1 therapies, weight-management protocols, and the inherited factors shaping each metabolic decision. Browse all Peptides & GLP-1 education

This comparison is editorially independent. PlexusDx has no commercial relationship with Eli Lilly or Novo Nordisk.

Zepbound and Wegovy are unusual in this category because both were brought to market specifically for chronic weight management — not diabetes first. That shared purpose makes the head-to-head especially relevant for anyone weighing obesity-treatment options. This article, current as of April 2026, contrasts their molecular design, weight-loss evidence, tolerability, cost, and the genetics that precede either.

Both engineered for weight management

Both Zepbound and Wegovy carry a chronic weight-management indication, which sets this comparison apart from diabetes-first pairings. Zepbound (tirzepatide, Eli Lilly) was approved for weight management in 2023, with a 2024 expansion into moderate-to-severe obstructive sleep apnea in adults with obesity. Wegovy (semaglutide 2.4 mg, Novo Nordisk) was approved for weight management in 2021 — in adults with BMI ≥ 30, or ≥ 27 with a weight-related condition.

Dual agonist versus GLP-1-selective

The molecules differ where it matters mechanically. Tirzepatide is a GIP and GLP-1 dual receptor agonist; semaglutide is a selective GLP-1 receptor agonist. Both act at the GLP-1 receptor across the pancreas, hypothalamus, and gut to slow gastric emptying and heighten satiety, but only tirzepatide also engages the GIP receptor — the added arm that separates the two designs.

STEP and SURMOUNT weight-loss data

Wegovy's weight-management evidence comes from the STEP program; Zepbound's comes from the SURMOUNT program, with SURMOUNT-OSA covering sleep apnea. Indirect comparisons have been drawn between STEP and SURMOUNT, and SURPASS evaluated tirzepatide against semaglutide 1 mg in type 2 diabetes. Because trial populations and endpoints differ, the reliable read stays per-trial rather than a blanket verdict.

Overlapping side effects

The tolerability picture overlaps heavily. Both carry the GLP-1 class boxed warning for thyroid C-cell tumor risk observed in rodent studies. Gastrointestinal effects — nausea, vomiting, diarrhea, constipation — are the most common and typically peak during dose escalation. Serious but less frequent events across the class include pancreatitis, gallbladder disease, and dehydration-related acute kidney injury.

Comparing the sticker prices

By U.S. list price as of April 2026, Zepbound runs approximately $1,059 per month (Eli Lilly published pricing) and Wegovy approximately $1,349 per month (Novo Nordisk published pricing). As always, out-of-pocket cost depends on insurance coverage, manufacturer savings cards, the indication on the prescription, and whether a compounded alternative is available through a licensed compounding pathway.

Inherited variables behind both

No matter which weight-management drug a clinician selects, the inherited groundwork is shared. Variants in GIPR (relevant to tirzepatide's GIP arm), GLP1R, FTO, and MC4R influence baseline appetite regulation, satiety, and energy balance. They are pathway-level markers that describe your metabolic starting point — not a forecast of how either compound will perform.

PlexusDx offers tirzepatide through its Weight Management Protocols, including the Tirzepatide protocol. The upstream context is what distinguishes the approach: before any GLP-1 pathway protocol, the Precision Peptide Genetic Test analyzes 14 pathways, 49 peptides, 150+ genetic insights — including GIPR, FTO, and MC4R variants that shape your baseline GLP-1, appetite-regulation, and energy-balance biology. That is the test before you invest approach.

Related reading on PlexusDx: Generic Wegovy, Coupons for Wegovy, Wegovy Discount, Wegovy GoodRx.

Disclaimer: This article is educational. PlexusDx offers tirzepatide through its Weight Management Protocols and covers the mechanism, evidence, and genetic context that inform any decision to use it. The Precision Peptide Genetic Test analyzes how your genes influence peptide-related biological pathways; it does not predict response to any specific medication. Consult a qualified healthcare provider before beginning any peptide protocol.

See the formats inside the PlexusDx Weight Management Protocols, or begin upstream with the Precision Peptide Genetic Test to map your GLP-1 pathway biology first.

Frequently Asked Questions

Are Zepbound and Wegovy both approved for weight loss?

Yes. Zepbound (tirzepatide) was approved for chronic weight management in 2023 and Wegovy (semaglutide 2.4 mg) in 2021, both for adults meeting BMI criteria. Zepbound also holds a 2024 indication for moderate-to-severe obstructive sleep apnea in adults with obesity, which Wegovy does not carry.

Which molecule is more potent by design?

Tirzepatide engages both GIP and GLP-1 receptors, while semaglutide engages GLP-1 alone. SURPASS-2 showed larger mean weight reduction with tirzepatide versus semaglutide 1 mg in type 2 diabetes, but weight-management trials used different endpoints, and individual response varies — discuss with a provider.

What accounts for the price difference?

As of April 2026, Wegovy's list price (about $1,349 per month) runs higher than Zepbound's (about $1,059 per month) per manufacturer pricing. List price is only a starting point; coverage, savings-card eligibility, and the prescription's indication shape what a patient actually pays out of pocket.

Can the genetic test tell me which one to choose?

No. The Precision Peptide Genetic Test analyzes pathway-level variants in GIPR and FTO, and MC4R that describe baseline GLP-1 and energy-balance biology. It is educational context that applies to both compounds, not a predictor of response to semaglutide, tirzepatide, or any medication.

This article is part of the PlexusDx Education Hub. Browse all Peptides & GLP-1 education

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance. References are included at the end of the article when scientific, medical, or health-related claims are discussed.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.